Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MB07803 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MB07803 | DRUG | Daily oral administration |
| Placebo | DRUG | Daily oral administration |
Inclusion Criteria: * Fasting plasma glucose between 120 - 270 mg/dL at screening * HbA1c measurements between 6.0 - 10% at screening * Females who are surgically sterile (i.e. women who have had a hysterectomy or tubal ligation). Females who are postmenopausal for at least 12 consecutive months an...
MB07803 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic that has been studied in a Phase 2 clinical trial. The drug is not approved and remains in clinical development.
MB07803 is being developed by Ligand Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker LGND. The company has conducted clinical research on this drug candidate for Type 2 Diabetes Mellitus.
MB07803 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not received regulatory approval.
MB07803 has been studied in one completed clinical trial, registered as NCT00458016. This Phase 2 study evaluated the safety, tolerability, and efficacy of MB07803 in patients with Type 2 Diabetes Mellitus. The trial enrolled 105 participants in the United States.
MB07803 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for Type 2 Diabetes Mellitus. The drug remains in clinical development and has not been authorized for commercial use.